Regina Rabinovich
Chair
Executive Committee Chair
Governance Committee Chair
Dr. Regina Rabinovich took on the role of the Sabin Vaccine Institute board chair in December 2020, after serving as a trustee since 2015 and chair of the Governance Committee since 2016. Dr. Rabinovich is currently the ExxonMobil Malaria Scholar in Residence at the Harvard T.H. Chan School of Public Health. In addition, she is chair of the Malaria Eradication Scientific Alliance at ISGlobal, University of Barcelona, where she also serves as director of the Malaria Elimination Initiative. Dr. Rabinovich has over three decades of experience in global health across research, public health and philanthropic sectors, with a focus on strategy, global health product development and the introduction and scale-up of tools and strategies resulting in impact on endemic populations.
From 2003-2012, Dr. Rabinovich served as director of the Infectious Diseases division at the Bill & Melinda Gates Foundation, overseeing the development and implementation of strategies for the prevention, treatment and control of infectious diseases of particular relevance to malaria, pneumonia, diarrhea and neglected infectious diseases. Dr. Rabinovich also served as chief of the Clinical and Regulatory Affairs Branch at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation of vaccines through a network of U.S. clinical research units. She participated in the Children’s Vaccine Initiative, a global effort to prevent infectious diseases in children in the developing world.
In 1999, Dr. Rabinovich became director of the PATH Malaria Vaccine Initiative, a project funded by the Bill & Melinda Gates Foundation to advance efforts to develop promising malaria vaccine candidates. She serves on the board of the Catholic Medical Mission Board.
Dr. Rabinovich holds a medical degree from Southern Illinois University and a master’s degree in public health from the University of North Carolina.
We make vaccines more accessible, enable innovation and expand immunization across the globe.